Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2006-12

AUTHORS

Amit Agrawal, John F R Robertson, K L Cheung

ABSTRACT

BACKGROUND: High dose estrogens (HDEs) were frequently used as endocrine agents prior to the introduction of tamoxifen which carries fewer side effects. Due to the development of resistance to available endocrine agents in almost all women with metastatic breast cancer, interest has renewed in the use of HDEs as yet another endocrine option that may have activity. We report our experience with one of the HDEs ("ethinylestradiol" 1 mg daily) in advanced breast cancer (locally advanced and metastatic) in post-menopausal women who had progressed on multiple endocrine agents. PATIENTS AND METHODS: According to a database of advanced breast cancer patients seen in our Unit since 1998, those who had complete set of information and fulfilled the following criteria were studied: (1) patients in whom further endocrine therapy was deemed appropriate i.e., patients who have had clinical benefit with previous endocrine agents or were not fit or unwilling to receive chemotherapy in the presence of potentially life-threatening visceral metastases; (2) disease was assessable by UICC criteria; (3) were treated with "ethinylestradiol" until they were withdrawn from treatment due to adverse events or disease progression. RESULTS: Twelve patients with a median age of 75.1 years (49.1-85 years) were identified. Majority (N = 8) had bony disease. They had ethinylestradiol as 3rd to 7th line endocrine therapy. One patient (8%) came off treatment early due to hepato-renal syndrome. Clinical benefit (objective response or durable stable disease for > or = 6 months) was seen in 4 patients (33.3%) with a median duration of response of 10+ (7-36) months. The time to treatment failure was 4 (0.5-36) months. CONCLUSION: Yet unreported, high dose "ethinylestradiol" is another viable therapeutic strategy in heavily pre-treated patients when further endocrine therapy is deemed appropriate. Although it tends to carry more side effects, they may not be comparable to those of other HDEs (such as diethylstilbestrol) or chemotherapy. More... »

PAGES

44

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/1477-7819-4-44

DOI

http://dx.doi.org/10.1186/1477-7819-4-44

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1033917230

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16834778


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agrawal", 
        "givenName": "Amit", 
        "id": "sg:person.01036236301.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036236301.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "John F R", 
        "id": "sg:person.07764637207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheung", 
        "givenName": "K L", 
        "id": "sg:person.016477423232.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016477423232.32"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1006185805079", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000717306", 
          "https://doi.org/10.1023/a:1006185805079"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.breast.2005.08.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001017334"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.breast.2005.08.022", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001017334"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(74)91364-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006753414"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/bcr436", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010302564", 
          "https://doi.org/10.1186/bcr436"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011360956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1010619225209", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011725288", 
          "https://doi.org/10.1023/a:1010619225209"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2004.07.035", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027051769"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(97)00178-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030310702"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1971.33", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033932369", 
          "https://doi.org/10.1038/bjc.1971.33"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.1971.33", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033932369", 
          "https://doi.org/10.1038/bjc.1971.33"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198101013040104", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037574283"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jsbmb.2004.12.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050101750"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.2.5973.711", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051594563"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jcem.80.10.7559875", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064319145"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074641688", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082226833", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082233451", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082983068", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-12", 
    "datePublishedReg": "2006-12-01", 
    "description": "BACKGROUND: High dose estrogens (HDEs) were frequently used as endocrine agents prior to the introduction of tamoxifen which carries fewer side effects. Due to the development of resistance to available endocrine agents in almost all women with metastatic breast cancer, interest has renewed in the use of HDEs as yet another endocrine option that may have activity. We report our experience with one of the HDEs (\"ethinylestradiol\" 1 mg daily) in advanced breast cancer (locally advanced and metastatic) in post-menopausal women who had progressed on multiple endocrine agents.\nPATIENTS AND METHODS: According to a database of advanced breast cancer patients seen in our Unit since 1998, those who had complete set of information and fulfilled the following criteria were studied: (1) patients in whom further endocrine therapy was deemed appropriate i.e., patients who have had clinical benefit with previous endocrine agents or were not fit or unwilling to receive chemotherapy in the presence of potentially life-threatening visceral metastases; (2) disease was assessable by UICC criteria; (3) were treated with \"ethinylestradiol\" until they were withdrawn from treatment due to adverse events or disease progression.\nRESULTS: Twelve patients with a median age of 75.1 years (49.1-85 years) were identified. Majority (N = 8) had bony disease. They had ethinylestradiol as 3rd to 7th line endocrine therapy. One patient (8%) came off treatment early due to hepato-renal syndrome. Clinical benefit (objective response or durable stable disease for > or = 6 months) was seen in 4 patients (33.3%) with a median duration of response of 10+ (7-36) months. The time to treatment failure was 4 (0.5-36) months.\nCONCLUSION: Yet unreported, high dose \"ethinylestradiol\" is another viable therapeutic strategy in heavily pre-treated patients when further endocrine therapy is deemed appropriate. Although it tends to carry more side effects, they may not be comparable to those of other HDEs (such as diethylstilbestrol) or chemotherapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/1477-7819-4-44", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1032056", 
        "issn": [
          "1477-7819"
        ], 
        "name": "World Journal of Surgical Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "4"
      }
    ], 
    "name": "Efficacy and tolerability of high dose \"ethinylestradiol\" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents", 
    "pagination": "44", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "a1927426a4d4d0ba207692d379659f5b353fa2f11e423d1eb64ab61c8b93399c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16834778"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101170544"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/1477-7819-4-44"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1033917230"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/1477-7819-4-44", 
      "https://app.dimensions.ai/details/publication/pub.1033917230"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T18:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000514.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1186%2F1477-7819-4-44"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-44'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-44'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-44'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-44'


 

This table displays all metadata directly associated to this object as RDF triples.

136 TRIPLES      21 PREDICATES      46 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/1477-7819-4-44 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author Ned17116964c24add866043682a57cc96
4 schema:citation sg:pub.10.1023/a:1006185805079
5 sg:pub.10.1023/a:1010619225209
6 sg:pub.10.1038/bjc.1971.33
7 sg:pub.10.1186/bcr436
8 https://app.dimensions.ai/details/publication/pub.1074641688
9 https://app.dimensions.ai/details/publication/pub.1082226833
10 https://app.dimensions.ai/details/publication/pub.1082233451
11 https://app.dimensions.ai/details/publication/pub.1082983068
12 https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f
13 https://doi.org/10.1016/j.breast.2005.08.022
14 https://doi.org/10.1016/j.ejca.2004.07.035
15 https://doi.org/10.1016/j.jsbmb.2004.12.005
16 https://doi.org/10.1016/s0140-6736(74)91364-6
17 https://doi.org/10.1016/s0959-8049(97)00178-0
18 https://doi.org/10.1056/nejm198101013040104
19 https://doi.org/10.1136/bmj.2.5973.711
20 https://doi.org/10.1210/jcem.80.10.7559875
21 schema:datePublished 2006-12
22 schema:datePublishedReg 2006-12-01
23 schema:description BACKGROUND: High dose estrogens (HDEs) were frequently used as endocrine agents prior to the introduction of tamoxifen which carries fewer side effects. Due to the development of resistance to available endocrine agents in almost all women with metastatic breast cancer, interest has renewed in the use of HDEs as yet another endocrine option that may have activity. We report our experience with one of the HDEs ("ethinylestradiol" 1 mg daily) in advanced breast cancer (locally advanced and metastatic) in post-menopausal women who had progressed on multiple endocrine agents. PATIENTS AND METHODS: According to a database of advanced breast cancer patients seen in our Unit since 1998, those who had complete set of information and fulfilled the following criteria were studied: (1) patients in whom further endocrine therapy was deemed appropriate i.e., patients who have had clinical benefit with previous endocrine agents or were not fit or unwilling to receive chemotherapy in the presence of potentially life-threatening visceral metastases; (2) disease was assessable by UICC criteria; (3) were treated with "ethinylestradiol" until they were withdrawn from treatment due to adverse events or disease progression. RESULTS: Twelve patients with a median age of 75.1 years (49.1-85 years) were identified. Majority (N = 8) had bony disease. They had ethinylestradiol as 3rd to 7th line endocrine therapy. One patient (8%) came off treatment early due to hepato-renal syndrome. Clinical benefit (objective response or durable stable disease for > or = 6 months) was seen in 4 patients (33.3%) with a median duration of response of 10+ (7-36) months. The time to treatment failure was 4 (0.5-36) months. CONCLUSION: Yet unreported, high dose "ethinylestradiol" is another viable therapeutic strategy in heavily pre-treated patients when further endocrine therapy is deemed appropriate. Although it tends to carry more side effects, they may not be comparable to those of other HDEs (such as diethylstilbestrol) or chemotherapy.
24 schema:genre research_article
25 schema:inLanguage en
26 schema:isAccessibleForFree true
27 schema:isPartOf N4cea0d4515c7448ba46c675815ad6d4d
28 N5f732410d7cb49ee9e790d0e62a6090a
29 sg:journal.1032056
30 schema:name Efficacy and tolerability of high dose "ethinylestradiol" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents
31 schema:pagination 44
32 schema:productId N57c0e0c7a18e4bae97aacd4ab6e9ca4a
33 N592e59f442f1463e97cafd47e137d2e8
34 N5daa7bf0a1474717a731cb7e71ed4249
35 Ncf74a8e9517f4070ac3e8953c8763891
36 Nd7c7475b9b0b4bf6918757fb1e458e74
37 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033917230
38 https://doi.org/10.1186/1477-7819-4-44
39 schema:sdDatePublished 2019-04-10T18:21
40 schema:sdLicense https://scigraph.springernature.com/explorer/license/
41 schema:sdPublisher Nae74f3c9cd3d4552859d2108b892a929
42 schema:url http://link.springer.com/10.1186%2F1477-7819-4-44
43 sgo:license sg:explorer/license/
44 sgo:sdDataset articles
45 rdf:type schema:ScholarlyArticle
46 N4cea0d4515c7448ba46c675815ad6d4d schema:volumeNumber 4
47 rdf:type schema:PublicationVolume
48 N57c0e0c7a18e4bae97aacd4ab6e9ca4a schema:name doi
49 schema:value 10.1186/1477-7819-4-44
50 rdf:type schema:PropertyValue
51 N592e59f442f1463e97cafd47e137d2e8 schema:name readcube_id
52 schema:value a1927426a4d4d0ba207692d379659f5b353fa2f11e423d1eb64ab61c8b93399c
53 rdf:type schema:PropertyValue
54 N5daa7bf0a1474717a731cb7e71ed4249 schema:name nlm_unique_id
55 schema:value 101170544
56 rdf:type schema:PropertyValue
57 N5f732410d7cb49ee9e790d0e62a6090a schema:issueNumber 1
58 rdf:type schema:PublicationIssue
59 N996aae4a0e84417eb839594ba7ce597d schema:name Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK
60 rdf:type schema:Organization
61 Na86e0fcdfb3449b1b3fac2878db190b8 schema:name Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK
62 rdf:type schema:Organization
63 Nae74f3c9cd3d4552859d2108b892a929 schema:name Springer Nature - SN SciGraph project
64 rdf:type schema:Organization
65 Nbb319de6ebb8428e85d0dd819f48c725 rdf:first sg:person.016477423232.32
66 rdf:rest rdf:nil
67 Ncf74a8e9517f4070ac3e8953c8763891 schema:name pubmed_id
68 schema:value 16834778
69 rdf:type schema:PropertyValue
70 Nd5543d0decee46be9e8e3ed111eb5334 rdf:first sg:person.07764637207.20
71 rdf:rest Nbb319de6ebb8428e85d0dd819f48c725
72 Nd7c7475b9b0b4bf6918757fb1e458e74 schema:name dimensions_id
73 schema:value pub.1033917230
74 rdf:type schema:PropertyValue
75 Ned17116964c24add866043682a57cc96 rdf:first sg:person.01036236301.85
76 rdf:rest Nd5543d0decee46be9e8e3ed111eb5334
77 Nfea5f90e856348118232692c316d91a5 schema:name Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK
78 rdf:type schema:Organization
79 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
80 schema:name Medical and Health Sciences
81 rdf:type schema:DefinedTerm
82 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
83 schema:name Oncology and Carcinogenesis
84 rdf:type schema:DefinedTerm
85 sg:journal.1032056 schema:issn 1477-7819
86 schema:name World Journal of Surgical Oncology
87 rdf:type schema:Periodical
88 sg:person.01036236301.85 schema:affiliation Na86e0fcdfb3449b1b3fac2878db190b8
89 schema:familyName Agrawal
90 schema:givenName Amit
91 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036236301.85
92 rdf:type schema:Person
93 sg:person.016477423232.32 schema:affiliation Nfea5f90e856348118232692c316d91a5
94 schema:familyName Cheung
95 schema:givenName K L
96 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016477423232.32
97 rdf:type schema:Person
98 sg:person.07764637207.20 schema:affiliation N996aae4a0e84417eb839594ba7ce597d
99 schema:familyName Robertson
100 schema:givenName John F R
101 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20
102 rdf:type schema:Person
103 sg:pub.10.1023/a:1006185805079 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000717306
104 https://doi.org/10.1023/a:1006185805079
105 rdf:type schema:CreativeWork
106 sg:pub.10.1023/a:1010619225209 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011725288
107 https://doi.org/10.1023/a:1010619225209
108 rdf:type schema:CreativeWork
109 sg:pub.10.1038/bjc.1971.33 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033932369
110 https://doi.org/10.1038/bjc.1971.33
111 rdf:type schema:CreativeWork
112 sg:pub.10.1186/bcr436 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010302564
113 https://doi.org/10.1186/bcr436
114 rdf:type schema:CreativeWork
115 https://app.dimensions.ai/details/publication/pub.1074641688 schema:CreativeWork
116 https://app.dimensions.ai/details/publication/pub.1082226833 schema:CreativeWork
117 https://app.dimensions.ai/details/publication/pub.1082233451 schema:CreativeWork
118 https://app.dimensions.ai/details/publication/pub.1082983068 schema:CreativeWork
119 https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f schema:sameAs https://app.dimensions.ai/details/publication/pub.1011360956
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1016/j.breast.2005.08.022 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001017334
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1016/j.ejca.2004.07.035 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027051769
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1016/j.jsbmb.2004.12.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050101750
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1016/s0140-6736(74)91364-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006753414
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1016/s0959-8049(97)00178-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030310702
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1056/nejm198101013040104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037574283
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1136/bmj.2.5973.711 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051594563
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1210/jcem.80.10.7559875 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064319145
136 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...